These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 25546777)

  • 21. Vaccines in the assessment of patients for immune deficiency.
    Ballow M
    J Allergy Clin Immunol; 2012 Jul; 130(1):283-4.e5. PubMed ID: 22742841
    [No Abstract]   [Full Text] [Related]  

  • 22. Acute renal dysfunction caused by nonsucrose intravenous immunoglobulin in common variable immunodeficiency.
    Kim AS; Broide DH
    Ann Allergy Asthma Immunol; 2017 Feb; 118(2):231-233. PubMed ID: 28024991
    [No Abstract]   [Full Text] [Related]  

  • 23. Intravenous immunoglobulin therapy: how does IgG modulate the immune system?
    Schwab I; Nimmerjahn F
    Nat Rev Immunol; 2013 Mar; 13(3):176-89. PubMed ID: 23411799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous immunoglobulin therapy in dermatologic disorders.
    Cakmak SK; Gül U; Gönül M; Kiliç A; Soylu S
    Inflamm Allergy Drug Targets; 2008 Jun; 7(2):75-84. PubMed ID: 18691136
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-inflammatory actions of intravenous immunoglobulin.
    Nimmerjahn F; Ravetch JV
    Annu Rev Immunol; 2008; 26():513-33. PubMed ID: 18370923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous immunoglobulin (IVIG)-mediated neutralisation of C5a: a direct mechanism of IVIG in the maintenance of a high Fc gammaRIIB to Fc gammaRIII expression ratio on macrophages.
    Konrad S; Baumann U; Schmidt RE; Gessner JE
    Br J Haematol; 2006 Aug; 134(3):345-7. PubMed ID: 16848778
    [No Abstract]   [Full Text] [Related]  

  • 27. The other side of immunoglobulin G: suppressor of inflammation.
    Aschermann S; Lux A; Baerenwaldt A; Biburger M; Nimmerjahn F
    Clin Exp Immunol; 2010 May; 160(2):161-7. PubMed ID: 20041883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Mechanisms of immune modulation in immune thrombocytopenia].
    Wahn V
    Infusionsther Transfusionsmed; 1993 Apr; 20 Suppl 1():81-5; discussion 86. PubMed ID: 8499756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Common variable immunodeficiency.
    de Almeida Barry LR; Forte WC
    Allergol Immunopathol (Madr); 2004; 32(2):89-91. PubMed ID: 15087097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous immunoglobulin therapy for autoimmune diseases.
    Arnson Y; Shoenfeld Y; Amital H
    Autoimmunity; 2009 Sep; 42(6):553-60. PubMed ID: 19657774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Managing patients with side effects and adverse events to immunoglobulin therapy.
    Azizi G; Abolhassani H; Asgardoon MH; Shaghaghi S; Negahdari B; Mohammadi J; Rezaei N; Aghamohammadi A
    Expert Rev Clin Pharmacol; 2016; 9(1):91-102. PubMed ID: 26496172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases.
    Kaveri SV; Dietrich G; Hurez V; Kazatchkine MD
    Clin Exp Immunol; 1991 Nov; 86(2):192-8. PubMed ID: 1934588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New insights into IVIg mechanisms and alternatives in autoimmune and inflammatory diseases.
    Norris PAA; Kaur G; Lazarus AH
    Curr Opin Hematol; 2020 Nov; 27(6):392-398. PubMed ID: 32868670
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sweet SIGNs: IgG glycosylation leads the way in IVIG-mediated resolution of inflammation.
    Brückner C; Lehmann C; Dudziak D; Nimmerjahn F
    Int Immunol; 2017 Dec; 29(11):499-509. PubMed ID: 29300958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of sialylation in the anti-inflammatory activity of intravenous immunoglobulin - F(ab')₂ versus Fc sialylation.
    Schwab I; Nimmerjahn F
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):97-9. PubMed ID: 25546778
    [No Abstract]   [Full Text] [Related]  

  • 36. [Mechanisms of action of intravenous immunoglobulins].
    Poehlau D; Postert T; Rieks M; Baier J; Nastos I; Amoiridis G; Schimrigk S; Hoffmann V; Przuntek H
    Fortschr Med; 1996 Nov; 114(31):420-4. PubMed ID: 9036095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subclinical infection and dosing in primary immunodeficiencies.
    Jolles S
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):67-9. PubMed ID: 25546767
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: correlations with clinical phenotype and polymorphism of the neonatal Fc receptor.
    Oksenhendler E
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):92-3. PubMed ID: 25546776
    [No Abstract]   [Full Text] [Related]  

  • 39. [Immunoglobulins and rules of passive-active prophylaxis].
    Bucholc B
    Przegl Epidemiol; 2003; 57(2):391-7. PubMed ID: 12910611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment with intravenous polyvalent immunoglobulins for autoimmune diseases in children].
    Karmochkine M
    Presse Med; 1998 Jun; 27(23):1153-8. PubMed ID: 9767798
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.